PgWellness-Logo

Metamucil Multi-health benefits

Metamucil® gives your patients health benefits of psyllium fibre that go beyond irregularity:

  • - Helps support healthy blood sugar levels
  • - Helps lower cholesterol† to promote heart health
  • - Helps to temporarily suppress appetite§ before a meal
  • - Helps to reduce joint pain associated with osteoarthritis

† Lowers mildly to moderately elevated cholesterol levels when taken with a low-fat diet
§ Applies only to powdered formulations of Metamucil excluding Metamucil Fiber + Collagen.

Metamucil supports healthy blood sugar levels

Significant Reduction of Blood Glucose, HbA1C%, and Fasting Insulin After 6 Month Trial1

Psyllium husk is clinically proven to help support healthy blood sugar levels1**

Results after 6 months - difference in change from baseline for psyllium vs. diet:1

  • Fasting Blood Glucose: -18%‡ p<0.01
  • HbA1c: -0.7 units‡ p<0.01
  • Fasting Insulin: -17%‡ p<0.01

Chart adapted from Cicero et al.1


** As part of a diet

1.A randomized, controlled, parallel 6 month trial with metabolic syndrome patients. Patients were randomized to three treatment groups: American Heart Association Step 2 Diet n=45, American Heart Association Step 2 Diet + Psyllium 3.5g BID n=46, American Heart Association Step 2 Diet + Partially Hydrolysed Guar Gum 3.5 g BID n=46.

Metamucil improves serum lipid profiles

SIGNIFICANT REDUCTION IN
TOTAL-C AND LDL-C VS. PLACEBO OVER 6 MONTHS IN HYPERCHOLESTEROLEMIC PATIENTS2

Significant serum lipid reductions vs. placebo2

  • Total-C concentrations were 4.7% lower in the Metamucil group vs. the placebo group (p<0.001)
  • LDL-C concentrations were 6.7% lower in the Metamucil group vs. the placebo group (p<0.001)

SIGNIFICANT REDUCTION IN
TOTAL-C AND LDL-C VS. PLACEBO IN AN 8-WEEK META-ANALYSIS WITH HYPERCHOLESTEROLEMIC PATIENTS3

Significant serum lipid reductions vs. placebo3

  • Total-C was decreased by -3.8% in the Metamucil group vs. the placebo group (p<0.0001)
  • LDL-C was decreased by -6.6% in the Metamucil group vs. the placebo group (p<0.0001)

2. A double-blind, placebo-controlled, parallel, multicenter study evaluated the long-term effectiveness of Metamucil (5.1 grams twice daily, n= 197) and cellulose placebo (5.1 grams twice daily n= 51), as an adjunct to diet in the treatment of patients with primary hypercholesterolemia. Eligible patients completed an 8-week dietary adaptation phase with dietician counselling on AHA step 1 diet (weeks -8 to -1) followed by a 26-week treatment phase (weeks 0–26) and continued AHA step 1 diet with counselling.


3. A meta-analysis of 8 pivotal efficacy trials was conducted to evaluate the hypercholesterolemic effects of Metamucil (10.2 grams daily, n=384) and placebo (10.2 grams daily n=272) adjunctive to a low-fat diet for ≥ 8 weeks in individuals with mild-to-moderate hypercholesterolemia after a low-fat diet lead-in phase lasting ≥ 8 weeks.

Metamucil: sustained satiety

Greater fullness for 4 hours between meals with Metamucil vs. placebo

STUDY 1 INVESTIGATED SATIETY EFFECTS OF METAMUCIL VS. PLACEBO WITH NORMAL MEALS4††

  • Increased mean fullness from meals with Metamucil vs. placebo, over 4 hours

VAS – Desire to Eat Scale/Hunger Scale results

  • Hunger and desire to eat were consistently and significantly (P≤0.007) reduced for Metamucil vs. placebo**
  • There were no serious adverse events, or withdrawals due to adverse events, in the study

Study 2 confirms 4-hour satiety4,**

STUDY 2 CONFIRMED STUDY 1 SATIETY BENEFITS IN PATIENTS CONSUMING AN ENERGY-RESTRICTED BREAKFAST WITH 6.8 g OF METAMUCIL VS. PLACEBO

  • The SLIM Scale showed an increased mean fullness between meals with Metamucil vs. placebo, consistent over 4 hours

VAS Scales showed results similar to Study

  • Significant reductions were seen in 3-day mean hunger and desire to eat VAS results for the Metamucil group vs placebo (p ≤ 0.008)
  • The energy-restricted meal in Study 2 resulted in a decreased satiation response to the meal for both Metamucil and placebo

No serious AE or withdrawals due to AE occurred. Mild AEs were similar, with each group reporting 3 events.

METAMUCIL WITH BREAKFASTS INCREASED FULLNESS4††

Fullness from breakfast was 33% greater when patients took Metamucil vs. placebo

  • Metamucil’s decrease on the Mean VAS hunger scores was proportional to the decreased hunger from the meal. Metamucil decreased hunger by an additional 1/3 of the effect of the meal.

COMBINED RESULTS OF 6.8g METAMUCIL IN STUDY 1 & 24††

There were no serious AEs, or withdrawals due to AEs, reported in either study4

Metamucil supplementation before meals was well-tolerated and significantly increased satiety by: 4

  • > Increasing fullness
  • > Decreasing hunger
  • > Reducing the desire to eat between meals

**As part of a diet

††Scores averaged across all post-prandial measurement times and days were lower significantly or directionally (p ≤ 0.025 and p ≤ 0.052, respectively) for all psyllium doses vs. placebo.

4.Study 1: A single center, randomized, double-blind, placebo-controlled, 4-way cross-over study enrolled 30 healthy patients (19 men/11 women), 28 patients completed the study. Patients were randomized to 4 different groups: placebo and 3 different doses of psyllium fibre (3.4 g, 6.8 g, and 10.2 g) were taken before a controlled, regular breakfast and lunch. Patients spent 3 consecutive days in each group with a 4- to 5-day washout period between treatments. All patients received a single daily dose on their first day. The doses of 3.4 g and 6.8 g were given twice a day on the second and the third day. The dose of 10.2 g was given only once a day. All patients started the study receiving only 1 dose of psyllium fibre on the first day before breakfast to assess the potential impact of 3 single different doses on satiety responses. Three Satiety endpoints were self-assessed every half hour for a total of 19 per day: hunger and desire to eat on independent Visual Analog Scales (VAS) and hunger/fullness on the Satiety Labeled Intensity Magnitude (SLIM) scale. Study 2: A randomized, double-blind, placebo-controlled, 2-treatment, 3-period cross-over with a new group of patients. Forty-four healthy patients (25 men/19 women) were enrolled and 40 completed the study. Patients took 6.8 g of psyllium or placebo before receiving an energy-restricted breakfast. 6.8 g psyllium or placebo was given before lunch on days 1 & 2 but no dose before lunch on day 3. On each dosing day, patients consumed a breakfast providing an energy equivalent to 15%-20% of their estimated individual resting energy expenditure, but with the same proportions of carbohydrates, protein, and fibre as study 1 (50% carbohydrate, 34% fat, 16% protein). Satiety endpoints were assessed every 30 minutes by self-ratings of hunger and desire to eat on independent Visual Analog Scales (VAS) and hunger/fullness on the Satiety Labeled Intensity Magnitude (SLIM) scale.

References:

  • 1. Cicero AFG et al. Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Meiterr J Nutr Metab. 2010;3:47–57.
  • 2. Anderson JW et al. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 2000;71(6):1433-8.
  • 3. Anderson JW et al. Cholesterol lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000;71(2):472-9.
  • 4. Brum JM et al. Satiety effects of psyllium in healthy volunteers. Appetite 2016;(105):27–36.

METAMUCIL’S HEALTH BENEFITS ARE CLINICALLY STUDIED
AND TRUSTWORTHY

#1 DOCTOR RECOMMENDED FIBER BRAND FOR 9 YEARS IN A ROW‡

‡ Among recommendations in ProVoice™ surveys 2015 to 2023 (OTC Bulk Fibre category).